NLS Pharmaceutics announces new preclinical data for AEX-2

NLS Pharmaceutics (NLSP) announces new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist for narcolepsy and related neurological disorders. Key Preclinical Findings on AEX-2: Wakefulness Enhancement: AEX-2 significantly increased total wake duration while maintaining a stable wake architecture, avoiding excessive fragmentation. REM Sleep Preservation: Unlike traditional stimulants, AEX-2 regulated rapid eye movement sleep dynamics, minimizing undesired suppression and sleep rebound effects. Reduction in Cataplexy: AEX-2 effectively reduced the frequency and duration of cataplexy episodes, a crucial advancement for treating narcolepsy type 1. Expanding the AEX Platform: AEX-2 and AEX-41 in Neurodegeneration and Metabolic Disorders: Targeting Neuroinflammation: Recent discoveries highlight AEX compounds’ engagement with the Sigma-1 receptor, which plays a key role in neuroprotection, synaptic plasticity, and REM sleep regulation. Potential in ALS and Neurodegenerative Diseases: Sigma-1 receptor modulation, combined with orexin receptor activation, suggests AEX-41 may have applications in ALS and Parkinson’s disease, particularly in preserving motor function and reducing neuroinflammation. Addressing Diabetes-Associated Neurological Disorders.